NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free ITRM Stock Alerts $1.49 -0.01 (-0.67%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$1.47▼$1.5550-Day Range$1.43▼$1.8752-Week Range$0.62▼$2.50Volume53,337 shsAverage Volume448,904 shsMarket Capitalization$24.67 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Iterum Therapeutics alerts: Email Address Iterum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside302.7% Upside$6.00 Price TargetShort InterestBearish7.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.75) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector753rd out of 928 stocksPharmaceutical Preparations Industry356th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingIterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIterum Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.68% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Iterum Therapeutics has recently increased by 3.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITRM. Previous Next 3.2 News and Social Media Coverage News SentimentIterum Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iterum Therapeutics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Iterum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WayNanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront!See how with its ongoing expansion and development About Iterum Therapeutics Stock (NASDAQ:ITRM)Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More ITRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITRM Stock News HeadlinesMay 15 at 12:37 AM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)May 14 at 7:35 PM | markets.businessinsider.comBuy Rating Affirmed for Iterum Therapeutics on Strong Market Potential and Financial StabilityMay 14 at 9:03 AM | insidermonkey.comIterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call TranscriptMay 14 at 3:11 AM | finance.yahoo.comQ1 2024 Iterum Therapeutics PLC Earnings CallMay 13 at 10:36 AM | msn.comIterum Therapeutics Non-GAAP EPS of -$0.38 beats by $0.16May 13 at 7:00 AM | globenewswire.comIterum Therapeutics Reports First Quarter 2024 Financial ResultsMay 11, 2024 | americanbankingnews.comIterum Therapeutics (ITRM) to Release Earnings on MondayMay 6, 2024 | globenewswire.comIterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024April 29, 2024 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 29, 2024 | msn.comIterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenemApril 29, 2024 | globenewswire.comIterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 2, 2024 | finance.yahoo.comIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comIterum Therapeutics plc (ITRM) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Iterum Therapeutics PLC Earnings CallMarch 28, 2024 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comIterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024March 15, 2024 | globenewswire.comIterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatMarch 12, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 6, 2024 | finance.yahoo.comIterum Therapeutics Provides Business UpdateFebruary 28, 2024 | investing.comIterum Therapeutics PLC (ITRM)February 24, 2024 | msn.comIterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63February 1, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLCFebruary 1, 2024 | msn.comIterum Shareholders Reject Board’s Share Issuance ProposalJanuary 31, 2024 | msn.comIterum Therapeutics Announces Triumph in Phase 3 uUTI TrialSee More Headlines Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/15/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITRM CUSIPN/A CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+300.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,567.32% Return on Assets-91.23% Debt Debt-to-Equity Ratio3.63 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-3.12Miscellaneous Outstanding Shares16,560,000Free Float15,661,000Market Cap$24.83 million OptionableNot Optionable Beta2.33 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Corey N. Fishman (Age 59)President, CEO & Director Comp: $1.37MMs. Judith M. Matthews (Age 54)Chief Financial Officer Comp: $778.82kDr. Michael W. Dunne M.D. (Age 64)Strategic Advisor & Director Comp: $168.15kDr. Sailaja Puttagunta M.D. (Age 55)Chief Medical Officer Comp: $755.89kMr. Tom Loughman Ph.D.Senior Vice President of Technical OperationsMs. Louise BarrettSenior Vice President of Legal Affairs & SecretaryDr. Steven I. Aronin M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsForte BiosciencesNASDAQ:FBRXLisata TherapeuticsNASDAQ:LSTARenovoRxNASDAQ:RNXTOncternal TherapeuticsNASDAQ:ONCTUnity BiotechnologyNASDAQ:UBXView All CompetitorsInsidersMichael W DunneBought 25,000 shares on 12/22/2023Total: $35,000.00 ($1.40/share)Michael W DunneBought 20,000 shares on 11/22/2023Total: $40,600.00 ($2.03/share)Corey N FishmanBought 10,000 shares on 11/20/2023Total: $15,900.00 ($1.59/share)View All Insider Transactions ITRM Stock Analysis - Frequently Asked Questions Should I buy or sell Iterum Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITRM shares. View ITRM analyst ratings or view top-rated stocks. What is Iterum Therapeutics' stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for Iterum Therapeutics' shares. Their ITRM share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 302.7% from the stock's current price. View analysts price targets for ITRM or view top-rated stocks among Wall Street analysts. How have ITRM shares performed in 2024? Iterum Therapeutics' stock was trading at $1.97 at the beginning of the year. Since then, ITRM shares have decreased by 24.4% and is now trading at $1.49. View the best growth stocks for 2024 here. When is Iterum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ITRM earnings forecast. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics plc (NASDAQ:ITRM) announced its earnings results on Thursday, March, 28th. The company reported ($0.94) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.08. When did Iterum Therapeutics' stock split? Shares of Iterum Therapeutics reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN). When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITRM) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.